Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Part time trader, Basically long term investor, but here and there make some short term trades, (I'm still young, could digest some risk).
Former New Yorker, Love the state of Georgia!
"Prediction is very difficult, especially if it's about the future." Nils Bohr
Leading pharmaceutical companies invest billions of dollars each year in research and development with little or no guarantee of a return on their investment.
With the average cost of developing a new drug hitting the $800 million mark, accurately forecasting the market potential for new compounds is becoming an essential tool in long-term strategic planning.
Forecasting is also essential in understanding how the dynamics of a market are changing, evaluating licensing and acquisition opportunities for a particular therapeutic candidate, and raising the awareness of company executives of both current and potential future competitors.
Last, but not least, pharmaceutical product forecasting provides precious building blocks for modeling and simulation exercises that investment analysts need to conduct on a continuous bases to estimate return-on-investment decisions and fine tune their portfolios.
Pharma Reports specializes in modeling and publishing short and medium term event-impacted linear forecasts for both new and established drugs.
Since actual brand performance depends on how the marketing company allocates its resources and how the competition responds to changes in market shares, we revise our forecasts periodically as new data points become available.
Currently, I work as investment analyst at Seamist Capital. Previously, since 2006, I was on the sell-side, covering healthcare stocks as research analyst . The banks I have worked for include the Stanford Group, Madison Williams, Roth Capital, and WR Hambrecht. I have passed the FINRA exams for Series 7, 63, 86, and 87. Ranked 68 out of 5,536 bloggers and
217 out of 9,715 total experts on TipRanks with 75% success rate and 46.2% average returns.
A qualified Chartered Certified Accountant and a lover of classical music, my other great passion in life is the trading of shares. Always on the look out for under the radar stocks with great potential, I tend to focus on biotech companies but consider all potential hidden gems.
I have an undergraduate degree and a graduate degree in the field of Sociology and am a life long "student." I learned about investing through observation as my father invested my grandfather's small nest egg before I was born when grandpa died in 1958. Dad invested in Growth and Income companies so that Grandma would not run out of money and would have an income. When she died in 1978 she was worth nearly $1 million with about 60% of that being Philip Morris as it had outperformed everything else by a wide margin. At 17 I inherited about $9,000 and kept it invested and benefited from the dividends for spending money while in college and graduate school, then I had money for a downpayment on a house in my mid 20's and kept the rest invested. I was mainly buy and hold but wasn't a fan of the tobacco industry so weaned off the PM for cash needs and also bought other stocks, mainly pharmaceuticals. Up until this year I was mainly a buy and hold investor. I the past couple years I have become much more active in researching and managing my investments.
I love growth, especially with game changing companies like: NTCXF, ARTH and CLIR. I also have holdings in more traditional growth companies and ETFs--JNJ and TAN for instance.
Charles (Chuck) C. Carnevale is the creator of F.A.S.T. Graphs™. Chuck is also co-founder of an investment management firm. He has been working in the securities industry since 1970: he has been a partner with a private NYSE member firm, the President of a NASD firm, Vice President and Regional Marketing Director for a major AMEX listed company, and an Associate Vice President and Investment Consulting Services Coordinator for a major NYSE member firm. Prior to forming his own investment firm, he was a partner in a 30-year-old established registered investment advisory in Tampa, Florida. Chuck holds a Bachelor of Science in Economics and Finance from the University of Tampa. Chuck is a sought-after public speaker who is very passionate about spreading the critical message of prudence in money management. Chuck is a Veteran of the Vietnam War and was awarded both the Bronze Star and the Vietnam Honor Medal.
Founder of Investing Sidekick, a website that provides stock reports and analytical spreadsheets for investors. He has been working as a research analyst for 10 years and aims to share his analysis and insights with private investors.
I have a private small company with a few different revenue streams. I survive off of one particular stream and invest the other smaller streams into the market.
I consider myself a longterm value investor and am not risk averse. I have three seperate portfolios each holding one third of my capital.
My goal was to create a multiframed method of analysis that might allow the average retail investor to pick investments that have a high probability of doubling or tripling. I am willing to cut against the grain and take contrarian deep value bets based on price value inefficiencies. I would like to compound at 30% average yearly gains in an all of my accounts. I have had 2 years of compounding my money at over 300% in these accounts so I would be ahead of my current benchmarks. As of end of 2013.
However, I do not expect to be able to repeat my results over the long term by trading. In fact I expect to sometimes underperform the market as many of my ideas might take time to come to fruition. I will often use arbitrage opportunities or short term swings for smaller gains. I am working on fine tuning my methodology but I believe it is unique and should produce the minimum average of 30%. I am currently ahead in this race and can withstand a correction as my portfolio grows quickly. I am also willing to get defensive if need be to protect capital or even go 50%cash. I run this as a very concentrated portfolio.
One third of my capital goes in a DRIP that I average in monthly to seven companies. I change these companies yearly based on valuation and position size. I grow positions here over time and never want to hold more than 30 companies in this account.
One third goes into long term companies that I see huge growth potential.
One third is in speculative bio-tech, tech and just about anything else where I can understand the financial statement sheets on and has great possible momentum and catalysts.
I often find myself going against the current trends in the market as I see opportunity in others fear. That said I seem to invest in around 15 stocks at a time and try to focus investments into the company at the best value. I hope to earn a healthy return over the next ten years to twenty years.
I am also interested in working in the industry as a career change and am always open to advice. Anyone out there want a 36 year old intern with advanced degrees in other areas?
My main skills are finding deep value opportunities and lucrative swing trade opportunities. I seem to have found a lot of bottom entries even in today's markets. I am willing to learn, enjoy games/game theory, love to read and solve problems.
I am working on starting a limited partnership for 2015 or 2016 so that I can share my gifts with family and friends.
"What looks like a horrible disaster now could be an awesome opportunity." "Buy Cheap when the big funds and others are giving it away"
All the Best,
I approach investing as a social theorist and a cultural historian. As a result, I am a contrarian. Studying the history of financialization, I have to agree with value investors like Seth Klarman, George Soros, and John Quiggin that markets are ultimately inefficient. However, I am not an orthodox value-investor. I believe in diversified strategy so as to insure maximum gains while maintaining a "margin of safety." Understanding that markets will operate inefficiently, I sometimes find "playing the greater fool's game" will yield nice short term gains. I have been investing for five years and have had proven results. I offer unique insight on fundamentals that most analysts do not consider.
Cornelius Vanderbilt has done more than any other man to shape our idea of investing. He was the ultimate contrarian. As an investor he looked for both value and risk. His approach to markets is complex and contradictory but can be learned from.
B.A., NYU Gallatin School
M.A. CUNY Gradatuate Center [in progress]
I started a twitter. https://twitter.com/matt_finston
My goal is to bring exposure to business development companies (BDCs) that finance small to medium sized businesses, typically overlooked by banks. BDCs are an instrument for investors to earn healthy dividends by avoiding double taxation at the corporate level and allowing income to flow directly to each shareholder. Please see website link below for more information. Email: email@example.com Website: www.bdcbuzz.com Newsletter: www.bdcbuzz.com/contact-us.html
Darren owns ProActive Financial LLC where he provides Financial Planning and Analysis consulting services. Darren's education includes a Bachelors in Economics, an MBA, and a Certificate in Personal Financial Planning.
My background is in governance, valuation, and accounting.
I try to look at stocks as the sum of contractual rights provided by domicile and certificate of incorporation, and am always cautious about the potential for management or controller overreach.
I also spend a lot of time thinking about the limitations of accounting in presenting reality. I'm especially interested in the application of GAAP to make a company a more or less attractive prospect for investment than it actually is.
I'm primarily interested in long-only equities. I try to avoid announced M&A as I no longer like the risk distributions, but M&A will occasionally find me, when a security I own is involved in a control transaction.
I've been a securities analyst, both in and out of large institutions, for a number of years and I hope to continue to do this for the rest of my lifetime.
Founder of the school of Nouveau Shamanic Security Analysis (NSSA).
"He is no longer an analyst"
--- Sean Penn, 1999
"For he is the Kwisatz Haderach"
-- Alia Atreides, Dune, 1985
"He may have been asleep, but that was before you dropped a f*cking plane on his head and woke him up."
--Didi Giancano, Heaven's Prisoners, 1996
For the past 30 years, I have been involved in startups, as a founder, and active investor. My first company was purchased by Johnson & Johnson, which set the foundation for future investments.
My level of trading escalated after graduating from college, primarily as a result of my relationship with the founder of the Silicon Valley venture capital firm, Institutional Venture Partners, (Netflix, Twitter, Oracle). By focusing on VC backed companies, I soon learned the advantage of investing in promising companies before they became household names. My interest in startups has never waned, and has become my primary focus today.
Trader of equities and options for over 12 years. Proprietary trading strategy involving options and biotech with a very high win to loss ratio. SMID cap biotech. Passionate about science and cooking.
"Win or lose, everybody gets what they want out of the market. Some people seem to like to lose, so they win by losing money."
Tom Shaughnessy is owner of SecretCaps.com, an independent investor and analyst. He has been investing in the stock market since the age of twelve. His style is comprehensive and includes multi-layered research on a concentrated set of stocks. Tom enjoys constructive dialogue regarding various investment ideas and theories. Tom enjoys intensive research on prospective investments. This includes valuation estimates and modeling, CEO and management interviews, product and expansion overviews, future prospects, financial analysis and the current state of affairs at the company. Moreover, Tom's articles have a focus on micro-cap companies whose potential have flown under the radar. In his leisure time Tom enjoys playing racquetball on a competitive level. Twitter: Toms_119
Background in engineering, which after years quite honestly bored me. I consider myself a serial entrepreneur and avid day trader. Particularly interested in small biopharmaceutical & biotech. I travel extensively, and I do mean extensively and love every minute of it. Currently living between Singapore and Knoxville, TN.
Waiting for PVCT to get to $100 so I can retire. Doesn't seem like that will be too far away now!
I am an independent trader. I have been trading my own money for over 20 years.
I am focused on finding growth stocks that are priced like value stocks or stocks that are misunderstood or under followed. Generally, I buy stocks where I feel like my chances of losing money are low, but still offer the possibility of large gains. This almost always leads me to small and microcap cap stocks.
I joined Seeking Alpha to share some of my ideas with others. I hope they are profitable.
Please do your own due diligence and do not blindly buy stocks on Seeking Alpha articles alone (including mine).